FGI-103: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 33: | Line 33: | ||
[[Category:Benzofurans]] | [[Category:Benzofurans]] | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:FGI-103.svg|FGI-103 | |||
</gallery> | |||
Latest revision as of 21:02, 16 March 2025
FGI-103 is an experimental antiviral drug that is being developed for the treatment of viral infections. It is a small molecule that has been shown to have broad-spectrum antiviral activity against a number of different viruses, including influenza, SARS-CoV, MERS-CoV, and Ebola virus.
Mechanism of Action[edit]
FGI-103 works by inhibiting the replication of viruses. It does this by interfering with the function of the viral RNA polymerase, a key enzyme that viruses use to copy their genetic material. By blocking the activity of this enzyme, FGI-103 prevents the virus from replicating and spreading within the body.
Clinical Trials[edit]
FGI-103 has been tested in a number of preclinical studies and has shown promising results. In animal models of influenza, SARS-CoV, MERS-CoV, and Ebola virus infection, treatment with FGI-103 resulted in a significant reduction in viral load and improved survival.
Clinical trials in humans are currently underway to further evaluate the safety and efficacy of FGI-103.
Potential Applications[edit]
If proven safe and effective in clinical trials, FGI-103 could potentially be used to treat a wide range of viral infections. This could include emerging viral diseases, such as COVID-19, as well as more established infections, such as influenza.
See Also[edit]
| Filoviridae | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
